BGI NOVA™ Newborn Hereditary Hearing Loss Screening


Over 400 million, including 34 million children, live with disabling hearing loss, affecting their health and quality of life. Hearing loss is a common hearing disorder disease with high occurrence and complex causes. Genetic factors are responsible for over 50% of hearing loss encountered in neonates, and account for nearly 40% of childhood hearing loss.

BGI have established a neonatal hearing screening strategy combined with genetic test for early detection of hereditary deafness by collecting microscopic blood samples from newborns and extracting DNA for high-throughput sequencing. The risk of hearing impairment in newborns will assessed by combining bioinformatics analysis.


    Option 1: Newborns pregnant couples with normal phenotype; Option 2: Deafness or hearing loss patient population with a family history of deafness or hearing loss


    DBS; Blood


    Target Sequencing

Why Choose BGI NOVA™ Newborn Hereditary Hearing Loss Screening?

  • Avoiding drug-induced Hearing Loss
  • Avoiding late-onset hearing loss
  • Predicting the outcome of CI
  • Early detecton and Early intervention